

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

<sup>Pr</sup> **JAMP Linezolid**

Linezolid Tablets 600 mg

Antibacterial Agent

JAMP Pharma Corporation  
1310 rue Nobel  
Boucherville, Quebec  
J4B 5H3, Canada

Date of Preparation:  
September 13, 2021

Submission Control No: 248908

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS .....	8
DRUG INTERACTIONS.....	14
DOSAGE AND ADMINISTRATION.....	16
OVERDOSAGE.....	17
ACTION AND CLINICAL PHARMACOLOGY.....	17
STORAGE AND STABILITY.....	22
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	22
<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>23</b>
PHARMACEUTICAL INFORMATION.....	23
CLINICAL TRIALS.....	24
DETAILED PHARMACOLOGY.....	26
MICROBIOLOGY .....	27
TOXICOLOGY .....	31
REFERENCES.....	34
<b>PATIENT MEDICATION INFORMATION.....</b>	<b>35</b>

Pr JAMP Linezolid

Linezolid Tablets

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Nonmedicinal Ingredients</b>
Oral	Tablets/600 mg	Colloidal silicon dioxide, corn starch, hydroxypropylcellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, titanium dioxide.

**INDICATIONS AND CLINICAL USE**

JAMP Linezolid (linezolid) is indicated for:

Treatment of adult patients with the following infections, when caused by susceptible strains of the designated aerobic Gram-positive micro-organisms:

Note: JAMP Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS AND PRECAUTIONS).

**Vancomycin-Resistant *Enterococcus faecium* (VREF) Infections:** JAMP Linezolid is indicated for the treatment of the following infections when due to VREF:

- Intra-abdominal, skin and skin-structure, and urinary tract infections (including cases associated with concurrent bacteremia).

(See CLINICAL TRIALS section)

Note: This indication for VREF is based on non-comparative studies.

**Nosocomial pneumonia** caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant strains), or *Streptococcus pneumoniae* (penicillin-susceptible strains only).

**Community-acquired pneumonia** caused by *Streptococcus pneumoniae* (penicillin-susceptible strains only) including cases with concurrent bacteremia or *Staphylococcus aureus* (methicillin-susceptible and -resistant strains).

**Complicated skin and skin structure infections, including non-limb threatening diabetic foot infections, without concomitant osteomyelitis,** caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant strains), *Streptococcus pyogenes*, or *Streptococcus agalactiae*.

Note: Linezolid has not been studied in the treatment of necrotizing fasciitis or decubitus ulcers.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of JAMP Linezolid and other antibacterial drugs, JAMP Linezolid should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Prior to instituting treatment with JAMP Linezolid, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to JAMP Linezolid. In infections where concomitant Gram-negative and/or anaerobic pathogens are suspected or are known to be present, JAMP Linezolid must be used in combination with an appropriate antibiotic in order to provide adequate antimicrobial coverage.

If clinically indicated, treatment with JAMP Linezolid may be started empirically before results of susceptibility testing are available. Once culture results become available antimicrobial therapy can be adjusted accordingly.

Because the inappropriate use of antibiotics can increase organism resistance, prescribers should carefully consider alternatives before initiating treatment with JAMP Linezolid in an outpatient setting.

## **CONTRAINDICATIONS**

JAMP Linezolid (linezolid) tablets are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

### **Monoamine Oxidase Inhibitors**

JAMP Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product (see DRUG INTERACTIONS, Drug-Drug Interactions).

### **Potential Interactions Producing Elevation of Blood Pressure**

Unless patients are monitored for potential increases in blood pressure, JAMP Linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine, phenylpropanolamine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) (see DRUG INTERACTIONS, Drug-Drug Interactions).

### **Potential Serotonergic Interactions**

Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, JAMP Linezolid should not be administered to patients with carcinoid syndrome and/or patients taking any

of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT<sub>1</sub> receptor agonists (triptans), meperidine or buspirone (see DRUG INTERACTIONS, Drug-Drug Interactions).

## WARNINGS AND PRECAUTIONS

### **General**

The use of antibiotics may promote the overgrowth of nonsusceptible organisms. Should superinfection occur during therapy, appropriate measures should be taken.

Linezolid tablets have not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.

Large quantities of foods or beverages with high tyramine content should be avoided while taking JAMP Linezolid (see DRUG INTERACTIONS, Drug-Food Interactions for foods or beverages with high tyramine content).

In healthy volunteers, co-administration of rifampin with linezolid resulted in a 21% decrease in linezolid  $C_{max}$  and a 32% decrease in linezolid AUC (see DRUG INTERACTIONS, Drug-Drug Interactions, Antibiotics). The clinical significance of this interaction is unknown.

The safety and efficacy of linezolid given for longer than 28 days have not been evaluated in controlled clinical trials.

### **Lactic acidosis**

**Lactic acidosis has been reported with the use of linezolid. Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving linezolid should receive immediate medical attention.**

### **Mortality Imbalance in an Investigational Study in Patients with Catheter-Related Bloodstream Infections, including those with catheter-site infections**

An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426, 95% CI 0.970, 2.098]. While causality has not been established, this observed imbalance occurred primarily in linezolid-treated patients in whom either Gram-negative pathogens, mixed Gram-negative and Gram-positive pathogens, or no pathogen were identified at baseline, but was not seen in patients with Gram-positive infections only.

Linezolid is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.

Linezolid has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected; appropriate

concomitant therapy is also required when anaerobic pathogens are isolated (see INDICATIONS AND CLINICAL USE).

### **Serotonin Syndrome**

Very rare spontaneous reports of serotonin syndrome with co-administration of linezolid and serotonergic agents have been reported. Since there is limited experience with concomitant administration of linezolid and serotonergic agents (such as serotonin re-uptake inhibitors, tricyclic antidepressants and serotonin 5-HT<sub>1</sub> receptor agonists) physicians should be alert to the possibility of signs and symptoms of serotonin syndrome (e.g., hyperpyrexia, and cognitive dysfunction) in patients receiving such concomitant therapy (see CONTRAINDICATIONS, ADVERSE REACTION and DRUG INTERACTIONS, Drug-Drug Interactions, Serotonergic Agents).

### **Carcinogenesis and Mutagenesis**

See TOXICOLOGY, Carcinogenicity, Toxicology and Mutagenicity.

### **Endocrine and Metabolism Diabetes**

Some MAO inhibitors have been associated with hypoglycemic episodes in diabetic patients receiving insulin or oral hypoglycemic agents. While a causal relationship between linezolid and hypoglycemia has not been established, diabetic patients should be cautioned of potential hypoglycemic reactions when treated with linezolid. If hypoglycemia occurs, a decrease in the dose of insulin or oral hypoglycemic agent, or discontinuation of oral hypoglycemic agent, insulin, or linezolid may be required. Therefore, JAMP Linezolid should be used with caution in diabetics under treatment with this drug.

### **Gastrointestinal**

#### ***Clostridium difficile-associated disease***

*Clostridium difficile*-associated disease (CDAD) has been reported with use of many antibacterial agents, including linezolid. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth to *Clostridium difficile*. *Clostridium difficile* produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridium difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridium difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases (see ADVERSE REACTIONS section).

## **Hematologic**

### **Myelosuppression**

**Myelosuppression (anemia including pure red blood cell aplasia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Complete blood counts should be monitored at least weekly in patients who receive linezolid, particularly in those who receive linezolid for longer than two weeks, patients who are at increased risk for bleeding, those with pre-existing myelosuppression, those receiving concomitant drugs that produce bone marrow suppression, or decreased hemoglobin levels or platelet counts or function, or those with a chronic infection who have received previous or concomitant antibiotic therapy.**

**Discontinuation of therapy with JAMP Linezolid should be considered in patients who develop or have worsening myelosuppression.**

### **Animal Pharmacology**

Dose- and time-dependent myelosuppression, as evidenced by bone marrow hypocellularity, decreased hematopoiesis, and decreased levels of circulating erythrocytes, leukocytes, and platelets, has been seen in animal studies. The hematopoietic effects occurred at oral doses of 40 and 80 mg/kg/day in dogs and rats, respectively (at exposures approximately 0.6 times in the dog and equal in the rat to the expected human exposure based on AUC). Hematopoietic effects were reversible, although in some studies reversal was incomplete within the duration of the recovery period.

## **Neurologic**

Peripheral neuropathy has been reported primarily in patients treated for longer than the maximum recommended duration of 28 days with linezolid. When outcome was known, recovery was reported in only some cases following linezolid withdrawal.

If symptoms of peripheral neuropathy such as numbness, tingling, prickling sensations or burning pain occur, the continued use of linezolid should be weighed against the potential risk.

Convulsions have been reported to occur rarely in patients when treated with linezolid. In most of these cases, a history of seizures or risk factors for seizures was reported.

## **Ophthalmologic**

Optic neuropathy has been reported in patients treated with linezolid, primarily those treated for longer than the maximum recommended duration of 28 days. When outcome was known, recovery was reported in some cases following linezolid withdrawal. In cases of optic neuropathy that progressed to loss of vision, patients were treated for longer than the maximum recommended duration. Visual blurring has been reported in some patients treated with linezolid for less than 28 days.

**Visual function should be monitored in all patients taking linezolid for longer than the maximum recommended duration and in all patients reporting new visual symptoms regardless of length of therapy with linezolid.** If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmologic evaluation is recommended. If optic neuropathy occurs, the continued use of linezolid in these patients should be weighed against the potential risks.

## **Susceptibility/Resistance**

### **Development of Drug Resistant Bacteria**

Prescribing JAMP Linezolid in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

## **Special Populations**

**Pregnant Women:** There are no adequate and well-controlled studies in pregnant women. JAMP Linezolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nursing Women:** Linezolid and its metabolites are excreted in the milk of lactating rats. Concentrations in milk were similar to those in maternal plasma. It is not known whether linezolid is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when JAMP Linezolid is administered to a nursing woman.

**Pediatrics:** There are insufficient data on the safety and efficacy of linezolid in children and adolescents (< 18 years old) to establish dosage recommendations (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions - Pediatrics). Therefore, until further data are available, use of JAMP Linezolid in this age group is not recommended.

**Geriatrics:** Of the 2046 patients treated with linezolid in phase III comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients.

**Monitoring and Laboratory Tests:** Complete blood counts should be monitored at least weekly in patients who receive linezolid, particularly in those who receive linezolid for longer than two weeks, patients who are at increased risk for bleeding, those with pre-existing myelosuppression, those receiving concomitant drugs that produce bone marrow suppression, or decreased hemoglobin levels or platelet counts or function, or those with a chronic infection who have received previous or concomitant antibiotic therapy (see WARNINGS AND PRECAUTIONS, Hematologic, Myelosuppression).

**Visual function should be monitored in all patients taking linezolid for longer than the maximum recommended duration and in all patients reporting new visual symptoms regardless of length of therapy with linezolid.** If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmologic evaluation is recommended (see WARNINGS AND PRECAUTIONS, Ophthalmologic).

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

The safety of linezolid was evaluated in 2046 adult patients enrolled in seven phase III comparator-controlled clinical trials, who were treated for up to 28 days. In these studies, 85% of the adverse events reported with linezolid were described as mild to moderate in intensity. The most common adverse events in patients treated with linezolid were diarrhea (incidence across studies: 2.8% to



11.0%), headache (incidence across studies: 0.5% to 11.3%), and nausea (incidence across studies: 3.4% to 9.6%).

Other adverse events reported in phase II and phase III studies included oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Phase III Clinical Trials:**

Table 1 shows the incidence of drug-related adverse events reported in at least 1% of adult patients in these trials by dose of linezolid.

**Table 1 Incidence of Drug-Related Adverse Events Occurring in >1% of Adult Patients Treated with Linezolid in Comparator -Controlled Clinical Trials**

Adverse Event	Uncomplicated Skin and Skin Structure Infections		All Other Indications	
	Linezolid 400 mg PO q12h (n=548)	Comparator (n=537)	Linezolid 600 mg q12h (n=1498)	All Other Comparators (n=1464)
% of patients with at least 1 drug-related adverse event	25.4	19.6	20.4	14.3
% of patients discontinuing due to drug-related adverse events <sup>†</sup>	3.5	2.4	2.1	1.7
Diarrhea	5.3	4.8	4	2.7
Nausea	3.5	3.5	3.3	1.8
Headache	2.7	2.2	1.9	1
Taste alteration	1.8	2	0.9	0.2
Vaginal moniliasis	1.6	1.3	1	0.4
Fungal Infection	1.5	0.2	0.1	<0.1
Abnormal liver function tests	0.4	0	1.3	0.5
Vomiting	0.9	0.4	1.2	0.4
Tongue discoloration	1.1	0	0.2	0
Dizziness	1.1	1.5	0.4	0.3
Oral moniliasis	0.4	0	1.1	0.4

<sup>†</sup> The most commonly reported drug-related adverse events leading to discontinuation in patients treated with linezolid were nausea, headache, diarrhea, and vomiting.

In controlled clinical trials, abdominal pain/cramp/distension and abnormal hematology tests were also reported occurring at an incidence of at least 1%.

**Less Common Clinical Trial Adverse Drug Reactions (<1%)**

Adverse drug reactions that were possibly or probably related to linezolid with an incidence less than 1.0% but greater than 0.1% in controlled clinical trials were:

<b>Body System</b>	
Metabolic and Nutritional	Amylase Increased, Hyperglycemia, Hyponatremia, Lipase High, Serum Creatine Phosphokinase Increased, AST Increased and ALT Increased
Special Senses	Blurred Vision, Tinnitus
Musculo-Skeletal	None
Hemic and Lymphatic	Eosinophilia, Neutropenia, Thrombocytopenia
Respiratory	None
Cardiovascular	Hypertension, Phlebitis
Digestive	Constipation, Dry Mouth, Dyspepsia, Gastritis, Glossitis, Increased Thirst, Stomatitis and Tongue Discoloration
Nervous	Dizziness, Hypesthesia, Insomnia, Paresthesia
Body as a whole	Abdominal Pain, Chills, Diaphoresis, Fatigue, Fungal Infection, Injection/Vascular Catheter Site Pain, and Injection/Vascular Catheter Site Phlebitis/Thrombophlebitis
Urogenital	Polyuria, and Vaginitis/Vaginal Infection
Skin	Dermatitis, Moniliasis Skin, Pruritus, Rash, and Urticaria

In controlled clinical trials the pattern of drug related adverse reactions by body system with an incidence less than 1.0% but greater than 0.1% were similar to comparators.

Serious adverse reactions in controlled clinical trials considered possibly or probably related to linezolid treatment with an incidence less than 0.1% were, Hypertension, Kidney Failure, Liver Function Test Abnormality, Pancreatitis, Thrombocytopenia, Transient Ischemic Attacks and Vomiting.

**Phase IV Clinical Trials:**

In a phase IV comparator-controlled study (Study 113) of adult diabetic patients with clinically documented complicated skin and skin structure infections (“diabetic foot infections”) (see CLINICAL TRIALS), most drug-related adverse events were rated as mild or moderate in intensity; 13.0% were rated as severe, and with the exception of diarrhea (0.8%), each severe drug related event was reported in no more than one patient.

**Table 2** Frequencies of Study-emergent Drug-Related Adverse Events Reported for  $\geq 1\%$  of Patients in Either Treatment Group [Study 113, linezolid in the treatment of adult diabetic patients with clinically documented complicated skin and skin structure infections ("diabetic foot infections")]

COSTART Body System Classification	Adverse Event (Medically Equivalent Term*)	Treatment Group	
		Linezolid N = 241 n (%) <sup>†</sup>	Comparator N = 120 n (%) <sup>†</sup>
Total Reported	Patients reporting at least 1 drug-related AE	64 (26.6)	12 (10.0)
Digestive	Diarrhea	18 (7.5)	4 (3.3)
	Nausea	14 (5.8)	0
	Vomiting	4 (1.7)	1 (0.8)
	Dyspepsia	3 (1.2)	1 (0.8)
	Appetite decreased	3 (1.2)	0
Hemic and Lymphatic	Anemia	11 (4.6)	0
	Thrombocytopenia	9 (3.7)	0

\* The information represents the number (%) of patients who reported a given study-emergent adverse event. Any patient with multiple reports of the same event was counted only once for that event.

<sup>†</sup> All percentages are based on the number of ITT patients.

### **Less Common Clinical Trial Adverse Drug Reactions (<1%)**

In Study 113, adverse drug reactions that were possibly or probably related to linezolid with an incidence less than 1.0% but greater than 0.1% were:

Body System	
Metabolic and Nutritional	Healing Abnormal, Hypoglycemia, Hypokalemia, LDH Increased
Special Senses	Taste Perversion
Musculo-Skeletal	None
Hemic and Lymphatic	Ecchymosis/Bruise, Neutropenia
Respiratory	Dyspnea
Cardiovascular	Congestive Heart Failure, Disorder Peripheral Vascular
Digestive	Anorexia, Biliary Pain, C. Difficile Colitis, Cholestatic Jaundice, Disorder Gastrointestinal NOS, Disorder Rectal, Flatulence, Gastrointestinal Bleeding, Monilia Oral
Nervous	Disorientation, Dizziness, Somnolence
Body as a whole	Abdominal Cramp, Abdominal Pain Localized, Asthenia, Disorder Mucous Membrane, Fatigue, Headache, Fungal Infection NOS, Infection NEC, Laboratory Test Abnormality Other
Urogenital	None
Skin	Dermatitis, Dermatitis Fungal, Erythema, Rash, Ulcer Skin

**Abbreviations:** NEC = not elsewhere classified; NOS = not elsewhere specified

In Study 113, serious drug-related events were reported for seven patients in the linezolid treatment group: congestive heart failure, peripheral vascular disease; biliary pain and cholestatic jaundice; *Clostridium difficile* colitis; gastrointestinal bleeding; anemia; and hypokalemia.

**Phase III Clinical Trials:**

**Abnormal Hematologic and Clinical Chemistry Findings**

Linezolid has been associated with thrombocytopenia when used in adults in doses up to and including 600 mg every 12 hours for up to 28 days. In phase III comparator-controlled trials, the percentage of patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 2.4% (range among studies: 0.3 to 10.0%) with linezolid and 1.5% (range among studies: 0.4 to 7.0%) with a comparator.

Thrombocytopenia associated with the use of linezolid appears to be dependent on duration of therapy (generally greater than 2 weeks of treatment). The platelet counts for most patients returned to the normal range/baseline during the follow-up period. No related clinical adverse events were identified in phase III clinical trials in patients developing thrombocytopenia.

Bleeding events were identified in thrombocytopenic patients in a compassionate use program for linezolid; the role of linezolid in these events cannot be determined (see WARNINGS AND PRECAUTIONS).

Changes seen in other laboratory parameters, without regard to drug relationship, revealed no substantial differences between linezolid and the comparators. These changes were generally not clinically significant, did not lead to discontinuation of therapy, and were reversible. The incidence of patients with at least one substantially abnormal hematologic or serum chemistry value is presented in Tables 3 and 4.

**Table 3 Percent of Adult Patients who Experienced at Least One Substantially Abnormal\* Hematology Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid**

Laboratory Assay	Uncomplicated Skin and Skin Structure Infections		All Other Indications	
	Linezolid 400 mg q12h	Comparator	Linezolid 600 mg q12h	All Other Comparators
Hemoglobin (g/L)	0.9	0.0	7.1	6.6
Platelet count (x 10 <sup>9</sup> /L)	0.7	0.8	3.0	1.8
WBC (x 10 <sup>9</sup> /L)	0.2	0.6	2.2	1.3
Neutrophils (x 10 <sup>6</sup> /L)	0.0	0.2	1.1	1.2

\* <75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and of baseline for values abnormal at baseline.

**Table 4 Percent of Adult Patients who Experienced at Least One Substantially Abnormal\* Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with linezolid**

Laboratory Assay	Uncomplicated Skin and Skin Structure Infections		All Other Indications	
	Linezolid 400 mg q12h	Comparator	Linezolid 600 mg q12h	All Other Comparators
AST (U/L)	1.7	1.3	5.0	6.8
ALT (U/L)	1.7	1.7	9.6	9.3
LDH (U/L)	0.2	0.2	1.8	1.5
Alkaline phosphatase (U/L)	0.2	0.2	3.5	3.1
Lipase (U/L)	2.8	2.6	4.3	4.2
Amylase (U/L)	0.2	0.2	2.4	2.0
Total bilirubin (µmol/L)	0.2	0.0	0.9	1.1
BUN (mmol/L)	0.2	0.0	2.1	1.5
Creatinine (µmol/L)	0.2	0.0	0.2	0.6

\* >2 x Upper Limit of Normal (ULN) for values normal at baseline;  
 >2 x ULN and >2 x baseline for values abnormal at baseline.

**Phase IV Clinical Trials:**

Table 5 shows the frequencies of selected abnormal hematologic test values in Study 113 at End of Treatment.

**Table 5 Frequencies of Abnormal Values for Selected Hematology Assays at EOT [Study 113, linezolid in the treatment of adult diabetic patients with clinically documented complicated skin and skin structure infections ("diabetic foot infections")]**

Hematology Assay	Clinically Significant Abnormal*/All abnormal values for assay	
	Linezolid n/N (%)	Comparator n/N (%)
Hemoglobin	9/111 (8.1)	1/52 (1.9)
Hematocrit	6/112 (5.4)	1/49 (2.0)
WBC	2/26 (7.7)	1/12 (8.3)
Platelet Count	9/43 (20.9)	3/16 (18.8)

**Abbreviations:** EOT=end of treatment, WBC= white blood count

\* Abnormal values assessed by the investigator as clinically significant.

Table 6 summarizes abnormal chemistry values in Study 113 assessed at End of Treatment.

**Table 6 Frequencies of Abnormal Values for Selected Chemistry Assays at EOT\* [(Study 113, linezolid in the treatment of adult diabetic patients with clinically documented complicated skin and skin structure infections ("diabetic foot infections"))]**

Chemistry Assay	Clinically Significant Abnormal*/All abnormal values for assay	
	Linezolid n/N (%) <sup>†</sup>	Comparator n/N (%)
ALT	3/32 (9.4)	1/15 (6.7)
AST	1/24 (4.2)	1/19 (5.3)
Bicarbonate.	1/22 (4.5)	0/15
Lactic dehydrogenase	3/38 (7.9)	0/16
Amylase	3/17 (17.6)	0/18

**Abbreviations:** ALT=Alanine aminotransferase, AST=Aspartate aminotransferase, EOT=end of treatment

\* Assessed by the investigator as clinically significant.

### **Post-Market Adverse Drug Reactions**

Myelosuppression (anemia including pure red blood cell aplasia, leukopenia, pancytopenia, sideroblastic anemia\* and thrombocytopenia) has been reported during post marketing use of linezolid (see WARNINGS AND PRECAUTIONS).

\* Primarily reported in patients receiving linezolid for more than the maximum recommended duration of 28 days

Peripheral neuropathy, and optic neuropathy sometimes progressing to loss of vision, have been reported in patients treated with linezolid. These reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days (see WARNINGS AND PRECAUTIONS).

Lactic acidosis (see WARNINGS AND PRECAUTIONS, General), convulsions (see WARNINGS AND PRECAUTIONS, Neurologic), angioedema and anaphylaxis have been reported.

Hypoglycemia, including symptomatic episodes, has been reported (see WARNINGS AND PRECAUTIONS).

Reports of bullous skin disorders including severe cutaneous adverse reactions such as toxic epidermal necrolysis and Stevens Johnson syndrome have been received.

Very rare spontaneous reports of serotonin syndrome with co-administration of linezolid and serotonergic agents have been reported (see WARNINGS AND PRECAUTIONS, Serotonin Syndrome).

These events have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to linezolid, or a combination of these factors. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made and causal relationship cannot be precisely established.

## **DRUG INTERACTIONS**

### **Overview**

**Drugs Metabolized by Cytochrome P450:** Linezolid is not an inducer of cytochrome P450 (CYP) in rats. It is not detectably metabolized by human cytochrome P450 and it does not inhibit the activities of clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Therefore, no CYP450-induced drug interactions are expected with linezolid. Concurrent administration of linezolid does not substantially alter the pharmacokinetic characteristics of (S)-warfarin, which is extensively metabolized by CYP2C9. Drugs such as warfarin and phenytoin, which are CYP2C9 substrates, may be given with linezolid without changes in dosage regimen.

## **Drug-Drug Interactions**

**Monoamine Oxidase Inhibition:** Linezolid is a mild reversible nonselective inhibitor of MAO-A and MAO-B. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Studies in healthy volunteers have examined the effect of linezolid on the pharmacodynamic responses to tyramine, sympathomimetic amines, and dextromethorphan (see CONTRAINDICATIONS).

**Adrenergic Agents:** A significant pressor response has been observed in normal adult subjects receiving linezolid and tyramine doses of more than 100 mg. Therefore, patients receiving linezolid need to avoid consuming large amounts of foods or beverages with high tyramine content.

Some individuals receiving linezolid may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response (see CONTRAINDICATIONS).

A reversible enhancement of the pressor response of either pseudoephedrine HCl (PSE) or phenylpropanolamine HCl (PPA) is observed when linezolid is administered to healthy normotensive subjects. A similar study has not been conducted in hypertensive patients. The interaction studies conducted in normotensive subjects evaluated the blood pressure and heart rate effects of placebo, PPA or PSE alone, linezolid alone, and the combination of steady-state linezolid (600 mg q12h for 3 days) with two doses of PPA (25 mg) or PSE (60 mg) given 4 hours apart. Heart rate was not affected by any of the treatments. Blood pressure was increased with both combination treatments. Maximum blood pressure levels were seen 2 to 3 hours after the second dose of PPA or PSE, and returned to baseline 2 to 3 hours after peak.

**Serotonergic Agents:** A study to assess the potential interaction of linezolid with a serotonin-reuptake inhibitor (dextromethorphan) was conducted in healthy volunteers. No significant differences were found in the pharmacodynamic measures of temperature, digit symbol substitution, nurse-rated sedation, blood pressure, or pulse when subjects were administered dextromethorphan with or without linezolid. The effects of other serotonin-reuptake inhibitors have not been studied. Very rare spontaneous reports of serotonin syndrome with co-administration of linezolid and serotonergic agents have been reported. Since there is limited experience with concomitant administration of linezolid and serotonergic agents, physicians should be alert to the possibility of signs and symptoms of serotonin syndrome (e.g., hyperpyrexia, and cognitive dysfunction) in patients receiving such concomitant therapy (see CONTRAINDICATIONS).

### **Antibiotics:**

**Aztreonam** - The pharmacokinetics of linezolid or aztreonam are not altered when administered together.

**Rifampin** - The effect of rifampin on the pharmacokinetics of linezolid was studied in sixteen healthy adult male volunteers administered linezolid 600 mg twice daily for 2.5 days with and without rifampin 600 mg once daily for 8 days. Rifampin decreased the linezolid C<sub>max</sub> and AUC by a mean 21% [90% CI, 15, 27] and a mean 32% [90% CI, 27, 37], respectively. The mechanism of this interaction and its clinical significance are unknown (see WARNINGS AND PRECAUTIONS, General).

Gentamicin - The pharmacokinetics of linezolid or gentamicin are not altered when administered together.

**Antacids:** No studies have been conducted with antacids and chelating agents. Based on the chemical structure, concurrent administration with these agents is not expected to affect absorption of linezolid.

**Drug-Food Interactions**

Large quantities of foods or beverages with high tyramine content should be avoided while taking linezolid. Quantities of tyramine consumed should be less than 100 mg per meal. Foods high in tyramine content include those that may have undergone protein changes by aging, fermentation, pickling, or smoking to improve flavor, such as aged cheeses (0 to 15 mg tyramine per 28 g); fermented or air-dried meats (0.1 to 8 mg tyramine per 28 g); sauerkraut (8 mg tyramine per 224 g); soy sauce (5 mg tyramine per 1 teaspoon); tap beers (4 mg tyramine per 360 mL); red wines (0 to 6 mg tyramine per 240 mL). The tyramine content of any protein-rich food may be increased if stored for long periods or improperly refrigerated.

**Drug-Herb Interactions**

Interactions with herbal products have not been established.

**Drug-Laboratory Interactions**

There are no reported drug-laboratory test interactions.

**DOSAGE AND ADMINISTRATION**

**Recommended Dose and Dosage Adjustment**

The recommended dosage for JAMP Linezolid tablets for the treatment of infections in adults is described in Table 7. Doses of JAMP Linezolid are administered every 12 hours (q12h).

**Table 7 Dosage Guidelines for JAMP Linezolid**

<b>Infection*</b>	<b>Dosage and Route of Administration</b>	<b>Recommended Duration of Treatment (consecutive days)</b>
Vancomycin-resistant <i>Enterococcus faecium</i> infections, including concurrent bacteremia	600 mg oral q12h	14 to 28
Nosocomial pneumonia	600 mg oral q12h	10 to 14
Complicated skin and skin structure infections: a) Except diabetic foot infections b) Non-limb threatening diabetic foot infections, without concomitant osteomyelitis	600 mg oral q12h 600 mg oral q12h	10 to 14 14 to 28
Community-acquired pneumonia, including concurrent bacteremia	600 mg oral q12h	10 to 14



\* due to the designated pathogens (see INDICATIONS AND CLINICAL USE)

Patients with infection due to MRSA should be treated with JAMP Linezolid 600 mg q12h.

In controlled clinical trials, the protocol-defined duration of treatment for all infections ranged from 7 to 28 days. Total treatment duration was determined by the treating physician based on site and severity of the infection, and on the patient's clinical response.

No dose adjustment is necessary when switching from intravenous to oral administration. Patients whose therapy is started with JAMP Linezolid injection may be switched to JAMP Linezolid tablets or oral suspension at the discretion of the physician, when clinically indicated.

JAMP Linezolid tablets may be taken with or without food.

### **Missed Dose**

If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Doses should not be doubled.

## **OVERDOSAGE**

In the event of overdose, supportive care is advised, with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination of linezolid. In a phase I clinical trial, approximately 30% of a dose of linezolid was removed during a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered. Data are not available for removal of linezolid with peritoneal dialysis or hemoperfusion. Clinical signs of acute toxicity in animals were decreased activity and ataxia in rats and vomiting and tremors in dogs treated with 3000 mg/kg/day and 2000 mg/kg/day, respectively.

For management of a suspected drug overdose, please contact your regional Poison Control Centre immediately.
--

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, with *in vitro* activity against aerobic gram-positive bacteria, certain gram-negative bacteria, and anaerobic microorganisms. Linezolid inhibits bacterial protein synthesis through a unique mechanism of action. Linezolid binds to sites on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The mechanism of action of linezolid (oxazolidinones) differs from that of other antibiotic classes (e.g., aminoglycosides, beta-lactams, folic acid antagonists, glycopeptides, lincosamides, quinolones, rifamycins, streptogramins, tetracyclines, chloramphenicol). Therefore, cross-resistance between linezolid and the mentioned classes of antibiotics is unlikely. Linezolid is active against selected gram positive bacteria that are susceptible or resistant to these antibiotics. *In*

*vitro* tests have shown that resistance to linezolid develops slowly via multiple-step mutations in the 23S ribosomal RNA and occurs at a frequency of  $1 \times 10^{-9}$  to  $1 \times 10^{-11}$ .

### **Pharmacokinetics**

The mean pharmacokinetic parameters of linezolid in adults after single and multiple oral and intravenous doses are summarized in Table 8. Plasma concentrations of linezolid at steady-state following oral dosing of 600 mg every 12 hours (q12h) are shown in Figure 1.

**Table 8 Mean (standard deviation) Pharmacokinetic Parameters of Linezolid in Adults**

Dose of Linezolid	C <sub>max</sub> (mcg/mL)	C <sub>min</sub> (mcg/mL)	T <sub>max</sub> (hrs)	AUC <sup>*</sup> (mcg • h/mL)	t <sub>1/2</sub> (hrs)	CL (mL/min)
<b>400 mg tablet</b>						
single dose †	8.10 (1.83)	---	1.52 (1.01)	55.10 (25.00)	5.20 (1.50)	146 (67)
bid dose	11.00 (4.37)	3.08 (2.25)	1.12 (0.47)	73.40 (33.50)	4.69 (1.70)	110 (49)
<b>600 mg tablet</b>						
single dose †	12.70 (3.96)	---	1.28 (0.66)	91.40 (39.30)	4.26 (1.65)	127 (48)
bid dose	21.20 (5.78)	6.15 (2.94)	1.03 (0.62)	138.00 (42.10)	5.40 (2.06)	80 (29)
<b>600 mg IV injection ‡</b>						
single dose	12.90 (1.60)	---	0.50 (0.10)	80.20 (33.30)	4.40 (2.40)	138 (39)
bid dose	15.10 (2.52)	3.68 (2.36)	0.51 (0.03)	89.70 (31.00)	4.80 (1.70)	123 (40)
<b>600 mg oral suspension</b>						
single dose	11.00(2.76)	---	0.97 (0.88)	80.80 (35.10)	4.60 (1.71)	141 (45)


\* AUC for single dose = AUC<sub>0-∞</sub>; for multiple-dose = AUC<sub>0-τ</sub>

† Data dose-normalized from 375 mg

‡ Data dose-normalized from 625 mg

C<sub>max</sub> = Maximum plasma concentration; C<sub>min</sub> = Minimum plasma concentration; T<sub>max</sub> = Time to C<sub>max</sub>; AUC = Area under concentration-time curve; t<sub>1/2</sub> = Elimination half-life; CL = Systemic clearance

The average minimum plasma concentrations (C<sub>min</sub>) at steady state for oral administration of 400 or 600 mg linezolid every 12 hours were 3.08 and 6.15 mcg/mL, respectively, and the corresponding average maximum concentrations (C<sub>max</sub>) were 11.0 and 21.2 mcg/mL, respectively. These results indicate that for these dose regimens, the C<sub>min</sub> values are near or above the highest MIC<sub>90</sub> (4 mcg/mL) for target microorganisms.



**Figure 1** Steady-State Linezolid Plasma Concentrations in Healthy Adults Following Oral Dosing of 600 mg (Tablets) Every 12 Hours (Mean ± Standard Deviation, n=16)

**Absorption:** Linezolid is rapidly and extensively absorbed after oral dosing. As shown in Figure 1, maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%. Therefore, linezolid may be given orally or intravenously without dose adjustment.

Linezolid may be administered without regard to the timing of meals. The time to reach the maximum concentration is delayed from 1.5 hours to 2.2 hours and  $C_{max}$  is decreased by about 17% when high fat food is given with linezolid. However, the total exposure measured as  $AUC_{0-\infty}$  values is similar under both conditions.

**Distribution:** Animal and human pharmacokinetic studies have demonstrated that linezolid readily distributes to well-perfused tissues. The plasma protein binding of linezolid is approximately 31% and is concentration-independent. The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.

Linezolid concentrations have been determined in various fluids from a limited number of subjects in Phase I volunteer studies following multiple dosing of linezolid. The ratio of linezolid in saliva relative to plasma was 1.2 to 1 and for sweat relative to plasma was 0.55 to 1. The ratio for epithelial lining fluid was 4.5 to 1, and for alveolar cells of the lung was 0.15 to 1, when measured at steady-state  $C_{max}$ . In a small study of subjects with ventricular-peritoneal shunts and essentially non-inflamed meninges, the ratio of linezolid in cerebrospinal fluid to plasma at  $C_{max}$  was 0.7 to 1 after multiple dosing of linezolid.

**Metabolism:** Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite (B). Formation of metabolite B is mediated by a non-enzymatic chemical oxidation mechanism *in vitro*. Linezolid is not an inducer of cytochrome P450

(CYP) in rats, and it has been demonstrated from *in vitro* studies that linezolid is not detectably metabolized by human cytochrome P450 and it does not inhibit the activities of clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4).

The lack of effect of linezolid to induce CYP2C9 was shown in a healthy volunteer study using warfarin as a metabolism probe.

**Excretion:** Nonrenal clearance accounts for approximately 65% of the total clearance of linezolid. Under steady-state conditions, approximately 30% of the dose appears in the urine as linezolid, 40% as metabolite B, and 10% as metabolite A. The renal clearance of linezolid is low (average 40 mL/min) and suggests net tubular reabsorption. Virtually no linezolid appears in the feces, while approximately 6% of the dose appears in the feces as metabolite B, and 3% as metabolite A.

A small degree of nonlinearity in clearance was observed with increasing doses of linezolid, which appears to be due to lower renal and nonrenal clearance of linezolid at higher concentrations. However, the difference in clearance was small and was not reflected in the apparent elimination half-life.

### **Special Populations and Conditions**

**Pediatrics:** Currently, there are limited data on the pharmacokinetics of linezolid during multiple dosing in pediatric patients of all ages. There are insufficient data on the safety and efficacy of linezolid in children and adolescents (< 18 years old). Further studies are needed to establish safe and effective dosage recommendations.

Pharmacokinetic studies indicate that after single and multiple doses in children (1 week to <12 years), linezolid clearance (based on kg body weight) was greater in pediatric patients than in adults, but decreased with increasing age.

In children 1 week to < 12 years old, administration of 10 mg/kg every 8 hours daily gave exposure approximating to that achieved with 600 mg twice daily in adults.

In neonates up to 1 week of age, the systemic clearance of linezolid (based on kg body weight) increases rapidly in the first week of life. Therefore, neonates given 10 mg/kg every 8 hours daily will have the greatest systemic exposure on the first day after delivery. However, excessive accumulation is not expected with this dosage regimen during the first week of life as clearance increases rapidly over that period.

In adolescents ( $\geq 12$  to <18 years old), linezolid pharmacokinetics were similar to that in adults following a 600 mg dose. Therefore, adolescents administered 600 mg every 12 hours daily will have similar exposure to that observed in adults receiving the same dosage.

**Geriatrics:** The pharmacokinetics of linezolid are not significantly altered in elderly patients (65 years or older). Therefore, dose adjustment for geriatric patients is not necessary.

**Gender:** Females have a slightly lower volume of distribution of linezolid than males. Plasma concentrations are higher in females than in males, which is partly due to body weight differences. After a 600 mg dose, mean oral clearance is approximately 38% lower in females than in males.

However, there are no significant gender differences in mean apparent elimination- rate constant or half-life. Thus, drug exposure in females is not expected to substantially increase beyond levels known to be well tolerated. Therefore, dose adjustment by gender is not necessary.

**Race:** The total clearance of linezolid is not influenced by race. Therefore, dose adjustment is not necessary for different races.

**Hepatic Insufficiency:** The pharmacokinetics of linezolid are not altered in patients (n=7) with mild-to-moderate hepatic insufficiency (Child-Pugh class A or B). On the basis of the available information, no dose adjustment is recommended for patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of linezolid in patients with severe hepatic insufficiency have not been evaluated.

**Renal Insufficiency:** The pharmacokinetics of the parent drug linezolid are not altered in patients with any degree of renal insufficiency. However, the two primary metabolites of linezolid may accumulate in patients with renal insufficiency, with the amount of accumulation increasing with the severity of renal dysfunction (see Table 9). The clinical significance of accumulation of these two metabolites has not been determined in patients with severe renal insufficiency. Because similar plasma concentrations of linezolid are achieved regardless of renal function, no dose adjustment is recommended for patients with renal insufficiency. However, given the absence of information on the clinical significance of accumulation of the primary metabolites, use of linezolid in patients with renal insufficiency should be weighed against the potential risks of accumulation of these metabolites. Both linezolid and the two metabolites are eliminated by dialysis. No information is available on the effect of peritoneal dialysis on the pharmacokinetics of linezolid. Approximately 30% of a dose was eliminated in a 3-hour dialysis session beginning 3 hours after the dose of linezolid was administered; therefore, linezolid should be given after hemodialysis.

**Table 9 Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Adult Patients with Varying Degrees of Renal Insufficiency After a Single 600-mg Oral Dose of Linezolid**

Parameter	Healthy Subjects CL <sub>CR</sub> > 80 mL/min	Moderate Renal Impairment 30 < CL <sub>CR</sub> < 80 mL/min	Severe Renal Impairment 10 < CL <sub>CR</sub> < 30 mL/min	Hemodialysis-Dependent	
				Off Dialysis*	On Dialysis
<b>Linezolid</b>					
AUC <sub>0-∞</sub> , mcg h/mL	110 (22)	128 (53)	127 (66)	141 (45)	83 (23)
t <sub>1/2</sub> , hours	6.4 (2.2)	6.1 (1.7)	7.1 (3.7)	8.4 (2.7)	7.0 (1.8)
<b>Metabolite A</b>					
AUC <sub>0-48</sub> , mcg h/mL	7.6 (1.9)	11.7 (4.3)	56.5 (30.6)	185 (124)	68.8 (23.9)
t <sub>1/2</sub> , hours	6.3 (2.1)	6.6 (2.3)	9.0 (4.6)	NA	NA
<b>Metabolite B</b>					
AUC <sub>0-48</sub> , mcg h/mL	30.5 (6.2)	51.1 (38.5)	203 (92)	467 (102)	239 (44)
t <sub>1/2</sub> , hours	6.6 (2.7)	9.9 (7.4)	11.0 (3.9)	NA	NA

\* between hemodialysis sessions  
NA = Not applicable

## **STORAGE AND STABILITY**

Store JAMP Linezolid tablets at controlled room temperature between 15°C - 30°C.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

JAMP Linezolid tablets are available in 600 mg (White to off-white, capsule shaped, biconvex, film coated tablets debossed “600” on one side and “JP” on other side. ) strengths and are supplied in bottles of 20 and 100 tablets and blister pack of 30 (3x10) tablets.

JAMP Linezolid tablets contain the following inactive ingredients: Colloidal silicon dioxide, corn starch, hydroxypropylcellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, titanium dioxide.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance


Common name: linezolid

Chemical name: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide

Molecular formula:  $C_{16}H_{20}FN_3O_4$

Molecular mass: 337.35 g/mol

Structural formula:



Physicochemical properties:

Physical Form: A white to off white crystalline powder

Solubility: Sparingly soluble in methanol and soluble in chloroform at  $25\text{ }^{\circ}\text{C} \pm 2\text{ }^{\circ}\text{C}$

pKa and pH values: The pKa value of Strong acid is 14.45 and pKa value of Strong base is - 0.66; pH 8.86 (1%) suspension, 7.90 (2%) suspension;

Melting range:  $177.0^{\circ}\text{C}$  to  $180.0^{\circ}\text{C}$

## CLINICAL TRIALS

### Comparative Bioavailability Studies

JAMP Linezolid (linezolid) tablets, 600 mg tablets have satisfied the criteria for a Biopharmaceutics Classification System (BCS)-based biowaiver in comparison to a Canadian Reference Product, Sandoz Linezolid (linezolid) tablets, 600 mg (Sandoz Canada Inc.).

Clinical studies have been conducted to establish in adults the safety and efficacy of linezolid for the treatment of infections described in the INDICATIONS AND CLINICAL USE section. This section provides clinical data for the indications of Vancomycin-Resistant *Enterococcus faecium* (VREF) infections and Complicated Skin and Skin Structure infections, Diabetic Foot infections only.

### Vancomycin-Resistant Enterococcal Infections

At the test-of-cure visit patients with vancomycin-resistant *Enterococcus faecium* (VREF) infections showed the following response rates for the population shown (Table 10):

**Table 10 Clinical Cure Rates at Test of Cure visit for Patients with VREF (Pooled VREF data)\***

Source of Infection	Intent-to-Treat Population n/N (%)	Clinically Evaluable Population n/N (%)	Microbiologically Evaluable Population n/N (%)
Intra-Abdominal Infection	31/34 (91.2)	30/32 (93.8)	30/32 (93.8)
Peritonitis @	13/15 (86.7)	13/14 (92.9)	13/14 (92.9)
Abdominal Infection @+	18/19 (94.7)	17/18 (94.4)	17/18 (94.4)
Skin and Skin Structure Infection	14/19 (73.7)	13/15 (86.7)	12/14 (85.7)
Urinary Tract Infection	12/18 (66.7)	10/11 (90.9)	9/10 (90.0)
Pneumonia	3/5 (60.0)	3/3 (100.0)	3/3 (100.0)
Bacteremia of Unknown Origin	16/22 (72.7)	15/20 (75.0)	12/17 (70.6)
Any Site With Associated Bacteremia	28/32 (87.5)	25/26 (96.2)	24/25 (96.0)
Any Site++	98/123 (79.7)	85/95 (89.5)	79/89 (88.8)

- \* 600 mg BID patients only
- @ Subsets of Intra-Abdominal Infection
- + Including abdominal abscess, abdominal/intra-abdominal infections, pelvic infections
- ++ All patients regardless of Source of Infection



## **Complicated Skin and Skin Structure Infections, Diabetic Foot Infections**

### **Study demographics and trial design**

**Table 11** Summary of trial design and patient demographics for Study 113, linezolid in the treatment of adult diabetic patients with clinically documented complicated skin and skin structure infections ("diabetic foot infections")

Study #	Trial design	Dosage, route of administration and duration *	Study subjects (Intent-to-Treat)	Mean age (Range)	Gender (% M/F)
766-INF-0026-113	Randomized (2:1 ratio), multi-center, open-label, comparator-controlled trial	Linezolid IV or oral – 600 mg BID, 7 to 28 consecutive days	241	63 (30-86)	71/29
		Ampicillin/sulbactam IV (1.5 to 3 g QID) or Amoxicillin/clavulanate IV (500 mg to 2 g QID) or oral (500 to 875 mg TID or BID) 7 to 28 consecutive days	120	62 (28-88)	71.7/28.3

\* Patients in the comparator group could also be treated with vancomycin IV 1 g q12h if MRSA was isolated from the foot infection. Patients in either treatment group who had Gram-negative bacilli isolated from the infection site could also receive aztreonam IV (1 to 2 g q8-12h). All patients were eligible to receive appropriate adjunctive treatment methods, such as debridement and off-loading, as typically required in the treatment of diabetic foot infections, and most patients received these treatments.

**Demographic Characteristics:** Treatment groups were similar with regard to disposition of patients by age, weight, race, sex and ethnicity. Diabetic patients in each treatment group were mostly white, male, and over 45 years of age.

### **Study results**

**Table 12** Clinical Cure Rates at Test of Cure Visit for IIT, MITT, CE and ME Populations in Study 113, linezolid in the treatment of adult diabetic patients with clinically documented complicated skin and skin structure infections ("diabetic foot infections")

Endpoints	Study Population	Assessment	Linezolid N = 241 n (%)*	Comparator N = 120 n (%)*	95% CI§
Patient clinical outcome [clinical cure rate at follow-up (test of cure)]	IIT	Success (cured)	165 (81.3)	77 (71.3)	-0.1, 20.1
		Number Assessed¶	203 (100)	108 (100)	
		Total	239	119	
	MITT	Success (cured)	124 (79.5)	61 (70.9)	-2.9, 20.1
		Number Assessed¶	156 (100)	86 (100)	
		Total	180	92	
	CE	Success (cured)	159 (82.8)	74 (73.3)	-0.6, 19.7

Endpoints	Study Population	Assessment	Linezolid N = 241 n (%) <sup>*</sup>	Comparator N = 120 n (%) <sup>*</sup>	95% CI <sup>§</sup>
		Number Assessed <sup>¶</sup>	192 (100)	101 (100)	0.2, 28.4
		Total	212	105	
	ME	Success (cured)	119 (81.0)	36 (66.7)	
		Number Assessed <sup>¶</sup>	147 (100)	54 (100)	
		Total	161	55	

Abbreviations: ITT = intent-to-treat, MITT = modified intent-to-treat, CE = clinically evaluable, ME = microbiologically evaluable

\* All percentages are based on the number of patients assessed.

§ Confidence interval for the difference in cure rates based on normal approximation, expressed as a percentage

¶ Excludes patients with Indeterminate or Missing outcomes.

The cure rates by pathogen for microbiologically evaluable patients are presented in Table 13.

**Table 13** Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Diabetic Foot Infections [Study 113, linezolid in the treatment of adult diabetic patients with clinically documented complicated skin and skin structure infections ("diabetic foot infections")]

Pathogen	Cured	
	Linezolid n/N (%)	Comparator n/N (%)
<i>Staphylococcus aureus</i>	49/64 (77)	20/30 (67)
Methicillin-resistant <i>S. aureus</i>	12/17 (71)	2/3 (67)
<i>Streptococcus agalactiae</i>	25/30 (83)	9/17 (53)
<i>Streptococcus pyogenes</i>	2/2 (100)	---

## DETAILED PHARMACOLOGY

### Animal Pharmacology

Linezolid has been studied in *in vitro* and *in vivo* animal models to evaluate the efficacy and safety profile. The intravenous and oral pharmacokinetic profiles are similar due to 100% oral bioavailability.

In animals the general pharmacological properties of linezolid were investigated to evaluate its effects on major physiological systems.

### **Central Nervous System Effects**

No biologically relevant effects were noted in the functional observational battery up to a single oral dose of 100 mg/kg in rats. At a single intravenous dose of 125 mg/kg, moderate decreases in activity parameters and urine and fecal output in females were noted 5 minutes postdose, and an increase in urine output was seen in females 3 hours postdose.

### **Cardiovascular Effects**

Intravenous 10 or 30 mg/kg doses of linezolid in anesthetized dogs produced no significant cardiovascular or respiratory changes.

### **Gastrointestinal and Renal System Effects**

Gastrointestinal effects of linezolid in rats were limited to a reduction in gastric emptying at single oral doses of 62.5 and 100 mg/kg. When administered intravenously, reduced gastric secretion and gastric emptying were noted at a dose of 125 mg/kg. No effects on urine volume or urinary excretion of sodium, potassium, or chloride were seen with intravenous doses of up to 125 mg/kg; increases in water consumption were observed in females with 30 and 125 mg/kg intravenous doses. No effects on intestinal contraction were observed in studies of isolated guinea pig ileum.

### **Monoamine Oxidase (MAO) Inhibition**

*In vitro* studies showed that linezolid is a weak and reversible (competitive) inhibitor of human MAO A and B with  $K_i$  values of 56  $\mu$ M and 0.71  $\mu$ M, respectively. The major metabolites had reduced affinity for MAO A and B, and also had reversible kinetics.

Large oral doses of crystalline tyramine, coadministered with 50 mg/kg oral doses of linezolid, were required to increase blood pressure in a rat model.

Administration of oral pseudoephedrine and phenylpropanolamine at 3-times the recommended clinical dose did not produce a clinically relevant vasopressor response in conscious, linezolid - pretreated dogs.

Linezolid was a weak inhibitor of serotonin and dopamine turnover in conscious rats. The magnitude of the changes induced by high doses of linezolid was small, compared to the irreversible MAO inhibitor clorgyline.

The physiologic and behavioral effects of linezolid in a rabbit model of the serotonin syndrome were determined. At 150 mg/kg, linezolid did not induce hyperthermia in the presence of a meperidine challenge, unlike the positive control, clorgyline.

## **MICROBIOLOGY**

Linezolid belongs to a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition. Linezolid targets the initiation phase of bacterial translation by preventing the formation of a functional 70S initiation complex. The action of linezolid is distinct from that of other protein synthesis inhibitors that inhibit elongation or termination. No inhibition of eukaryotic translation was observed in a cell-free mammalian translation system.

Linezolid has been shown to be active *in vitro* against most isolates of the organisms listed in Table 14.

**Table 14** *In vitro* Activity of Linezolid Against Aerobic and Facultative Gram-positive Microorganisms

Organism	No. Studies	No. Isolates	Weighted Average	
			MIC <sub>50</sub>	MIC <sub>90</sub>
<i>Staphylococcus aureus</i> (methicillin-susceptible)	9	916	1.8	2.5
<i>Staphylococcus aureus</i> (methicillin-resistant)	9	973	1.7	3.2
<i>Staphylococcus epidermidis</i> (methicillin-susceptible)	6	183	1.3	2.4
<i>Staphylococcus epidermidis</i> (methicillin-resistant)	6	216	1.2	2.1
<i>Enterococcus faecalis</i> (vancomycin-susceptible)	4	476	1.2	2.0
<i>Enterococcus faecalis</i> (vancomycin-resistant)	7	148	1.7	3.1
<i>Enterococcus faecium</i> (vancomycin-susceptible)	4	68	1.9	2.0
<i>Enterococcus faecium</i> (vancomycin-resistant)	6	252	1.3	2.4
<i>Streptococcus pneumoniae</i> (penicillin-susceptible)	5	303	0.6	1.0
<i>Streptococcus pneumoniae</i> (penicillin-intermediate)	4	242	0.6	1.0
<i>Streptococcus pneumoniae</i> (penicillin-resistant)	6	266	0.6	0.9
<i>Streptococcus agalactiae</i>	2	164	1.9	2.0
<i>Streptococcus pyogenes</i>	3	182	1.1	2.2

The following *in vitro* data are available, but their clinical significance is unknown. At least 90% of the following microorganisms exhibit an *in vitro* minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for linezolid. However, the safety and effectiveness of linezolid in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

#### **Aerobic and facultative Gram-positive microorganisms**

*Corynebacterium jeikeium* *Enterococcus casseliflavus* *Enterococcus gallinarum* *Listeria monocytogenes*

*Staphylococcus aureus* (vancomycin-intermediate strains)

*Staphylococcus haemolyticus* *Staphylococcus lugdunensis* *Streptococcus intermedius* Viridans group streptococci Group C streptococci

Group G streptococci

#### **Aerobic and facultative Gram-negative microorganisms**

*Pasteurella canis* *Pasteurella multocida*

#### **Anaerobic microorganisms**

*Peptostreptococcus anaerobius*

#### **“Other” microorganisms**

*Chlamydia pneumoniae*

In clinical trials, resistance to linezolid developed in 6 patients infected with *E. faecium* (4 patients received 200 mg q12h, lower than the recommended dose, and 2 patients received 600 mg q12h). In a compassionate use program, resistance to linezolid developed in 8 patients with *E. faecium* and in 1 patient with *E. faecalis*. All patients had either unremoved prosthetic devices or undrained abscesses. Resistance to linezolid occurs *in vitro* at a frequency of  $1 \times 10^{-9}$  to  $1 \times 10^{-11}$ . *In vitro* studies have shown that point mutations in the 23S rRNA are associated with linezolid resistance. Resistance to linezolid has not been seen in clinical trials in patients infected with *Staphylococcus* spp. or *Streptococcus* spp., including *S. pneumoniae*.

### Susceptibility Testing Methods

**NOTE:** Susceptibility testing by dilution methods requires the use of linezolid susceptibility powder. Linezolid Injection should not be used for susceptibility testing.

When available, the results of *in vitro* susceptibility test results for antimicrobial drugs used in the resident hospitals should be provided to the physician as periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

**Dilution Techniques:** Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure.

Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of linezolid powder. The MIC values should be interpreted according to criteria provided in Table 15.

**Table 15 Susceptibility Interpretive Criteria for Linezolid**

Pathogen	Susceptibility Interpretive Criteria					
	Minimal Inhibitory Concentrations (MIC in mcg/mL)			Disk Diffusion (Zone Diameters in mm)		
	S	I	R	S	I	R
<i>Enterococcus</i> spp	≤2	4	≥8	≥23	21-22	≤20
<i>Staphylococcus</i> spp <sup>a</sup>	≤4	---	---	≥21	---	---
<i>Streptococcus pneumoniae</i> <sup>a</sup>	≤2 <sup>b</sup>	---	---	≥21 <sup>c</sup>	---	---
<i>Streptococcus</i> spp other than <i>S. pneumoniae</i> <sup>a</sup>	≤2 <sup>b</sup>	---	---	≥21 <sup>c</sup>	---	---

- a The current absence of data on resistant strains precludes defining any categories other than “Susceptible”. Strains yielding test results suggestive of a “nonsusceptible” category should be retested, and if the result is confirmed, the isolate should be submitted to a reference laboratory for further testing.
- b These interpretive standards for *S. pneumoniae* and *Streptococcus* spp. other than *S. pneumoniae* are applicable only to tests performed by broth microdilution using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood inoculated with a direct colony suspension and incubated in ambient air at 35°C for 20 to 24 hours.
- c These zone diameter interpretive standards are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood inoculated with a direct colony suspension and incubated in 5% CO<sub>2</sub> at 35°C for 20 to 24 hours.

**Diffusion Techniques:** Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg of linezolid to test the susceptibility of microorganisms to linezolid. The disc diffusion interpretive criteria are provided in Table 15.

**Anaerobic Techniques:** For anaerobic bacteria, the susceptibility to linezolid as MICs can be determined by standardized test methods. Interpretive criteria for linezolid and anaerobic microorganisms have not been defined.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

### Quality Control

Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures. Standard linezolid powder should provide the following range of values noted in Table 16. **NOTE:** Quality control microorganisms are specific strains of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within bacteria; the specific strains used for microbiological quality control are not clinically significant.

**Table 16 Acceptable Quality Control Ranges for Linezolid to be Used in Validation of Susceptibility Test Results**

QC Strain	Acceptable Quality Control Ranges	
	Minimum Inhibitory Concentration(MIC in mcg/mL)	Disk Diffusion (Zone Diameters in mm)
<i>Enterococcus faecalis</i> ATCC 29212	1 - 4	Not applicable
<i>Staphylococcus aureus</i> ATCC 29213	1 - 4	Not applicable
<i>Staphylococcus aureus</i> ATCC 25923	Not applicable	27 - 31
<i>Streptococcus pneumoniae</i> ATCC 49619	0.50 - 2	28 - 34

## TOXICOLOGY

The toxicity of linezolid was evaluated in acute oral and IV toxicity studies in rats and an acute oral toxicity study in dogs, repeated-dose oral toxicity studies up to 6 months in duration in rats and 3 months in duration in dogs, a 4-week oral toxicity study in juvenile rats, repeated-dose IV toxicity studies up to 1 month in duration in rats and dogs, developmental and reproductive toxicity studies in mice and adult and juvenile rats, mutagenic potential studies *in vitro* and *in vivo*, and special toxicology studies (handler safety [ocular and dermal irritation] studies and MAO inhibition studies).

### Acute Toxicity

#### **Rat**

When the acute oral toxicity of linezolid was evaluated in rats given two equally divided doses of drug on one day, the minimum lethal oral dose was between 1000 - 3000 mg/kg/day. Clinical signs in surviving and moribund animals included decreased activity, ataxia, salivation, alopecia, and soiled face and urogenitalia. Suppressed or decreased body weight gain, which returned to normal by the end of the study, was observed at doses of 3000 and 5000 mg/kg/day. In surviving rats, the main gross findings consisted of enlarged cecum (a common effect in rats treated with antibiotics) and alopecia. No toxic signs or adverse effects were seen in acute IV toxicity studies when rats were administered dose levels of up to 400 mg/kg/day.

#### **Dog**

In male dogs given two equally divided doses of linezolid orally on one day, the minimum lethal dose was greater than 2000 mg/kg/day. Vomiting, tremors, and decreased activity were the primary clinical observations. No symptoms were observed twenty-four hours after the evening (PM) dose. Food consumption and body weight gains in dogs given 500 and 2000 mg/kg/day were suppressed slightly in the early phase of the observation period and returned to normal thereafter. Slight, transient elevations in serum alanine aminotransferase (ALT) were seen in one dog given 2000 mg/kg/day.

### Repeated-Dose Toxicity

Studies performed to assess the toxicity of linezolid after repeated dosing indicated that the primary target organs of toxicity were the hematopoietic and gastrointestinal systems in rats and dogs, and the reproductive system in rats. The NOAELs were 40 mg/kg/day in the 6-month oral rat study, 10 mg/kg/day in the 3-month oral rat study, 20 mg/kg/day in the 1-month oral rat study, and 20 mg/kg/day in the 1- and 3-month oral dog studies.

### Hematopoietic Effects

Linezolid produced myelosuppression in rats and dogs that was time- and dose-dependent, and reversible. Findings included mild bone marrow hypocellularity and moderate decreases in red blood cell, white blood cell, and platelet counts. A 1-month recovery period was sufficient for the reversal of myelosuppression in most studies, and in the case of the 3-month oral dose study in dogs, reversal of effects was observed during the dosing phase of the study when the dose was reduced from 40 to 30 mg/kg/day.

### **Gastrointestinal Effects**

Gastrointestinal effects were observed in rats and dogs that were likely primarily related to antibiotic-induced alterations in intestinal microflora. Findings in rats included decreased food consumption and diarrhea, which resulted in decreased weight gain, and histological changes in the large and small intestines (atrophy of intestinal mucosa and necrosis of epithelial cells in the intestinal crypts) in the 2-week study at high doses of 200 and 1000 mg/kg/day. In the longer term definitive studies in rats, treatment-related decreases in body weight gain and food consumption were not accompanied by microscopic findings. Reduced gastric emptying, noted in the safety pharmacology studies in rats, may have been a contributing factor to the inappetence. In dogs, anorexia, vomiting, and mucous stools accompanied weight loss. The gastrointestinal findings were not related to oral administration of linezolid, as they were also observed in the intravenous studies. All effects reversed with cessation of treatment.

### **Other Effects**

In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 male rats administered Linezolid at 80 mg/kg/day for 6 months, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The optic nerve degeneration observed was microscopically comparable to a spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of a common background change.

### **Carcinogenicity**

Linezolid will be used for short-term therapy. Therefore carcinogenicity bioassay studies have not been conducted.

### **Mutagenicity**

Linezolid is considered to be nonmutagenic and nonclastogenic, based on negative results in a battery of tests including those designed to measure chemically induced gene mutation in bacterial and mammalian cells (the Ames and AS52 assays, respectively) and those designed to measure chromosome aberrations in human lymphocytes *in vitro* and micronuclei in mouse bone marrow cells *in vivo*. In addition, linezolid did not induce unscheduled DNA synthesis (UDS) *in- vitro*, a measure of DNA repair following chemically induced DNA damage.

### **Reproduction and Teratology**

Linezolid did not affect the fertility or reproductive performance of adult female rats, while it reversibly decreased fertility in adult male rats when given orally at doses  $\geq 50$  mg/kg/day for 4 to 10 weeks with exposures approximately equal to or greater than the expected human exposure level (exposure comparisons are based on  $AUC_{0-24}$  in animals vs  $(2 \times AUC_{0-\tau})$  in humans given 600 mg twice daily). Epithelial cell hypertrophy in the epididymis may have contributed to the decreased fertility by affecting sperm maturation. Similar epididymal changes were not seen in dogs. Light microscopic examination of the testes did not show overt drug-induced effects, although an effect on spermatogenesis cannot be excluded. Although the concentrations of sperm in the testes were in the normal range, the concentrations in the cauda epididymis were decreased, and sperm from the vas



deferens had decreased motility.

Mildly decreased fertility occurred in juvenile male rats treated with linezolid orally through most of their period of sexual development (50 mg/kg/day from days 7 to 36 of age, and 100 mg/kg/day from days 37 to 55 of age, with exposures ranging from 0.4-fold to 1.2-fold that expected in humans based on AUC). No histopathological evidence of adverse effects was observed in the male reproductive tract.

In mice, embryo and fetal toxicity was seen only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). An oral dose of 450 mg/kg/day (6.5-fold the estimated human exposure level based on AUC) correlated with increased postimplantational embryo death, including total litter loss; decreased fetal body weights and an exacerbation of a normal genetic predisposition to sternal variations in the strain of mice used, in the form of an increased incidence of costal cartilage fusion.

In rats, mild fetal toxicity was observed at oral doses of 15 and 50 mg/kg/day (exposure levels 0.22-fold to approximately equivalent to the estimated human exposure, respectively, based on AUC). The effects consisted of decreased fetal body weights and reduced ossification of sternbrae, a finding often seen in association with decreased fetal body weights. Slight maternal toxicity, in the form of reduced body weight gain, was seen at 50 mg/kg/day.

In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered twice daily at total oral daily doses of 15 mg/kg/day (0.06-fold the estimated human exposure based on AUCs).

Linezolid was not teratogenic in mice, rats, or rabbits at exposure levels 6.5-fold (in mice), equivalent to (in rats), or 0.06-fold (in rabbits) the expected human exposure level, based on AUCs. However, embryo and fetal toxicities were seen.

When female rats were treated orally with 50 mg/kg/day of linezolid during pregnancy and lactation, survival of pups was decreased on postnatal days 1 to 4, and mild delays in maturational milestones were observed. Pups permitted to mature to reproductive age, when mated, showed evidence of a dose-related increase in preimplantation loss at maternal doses  $\geq 2.5$  mg/kg/day, with exposures below those expected in humans.

### **Other Studies**

In ocular and dermal irritation studies in albino rabbits, linezolid caused minimal and transient irritation when administered as a single dose of 100 mg/eye and was slightly irritating to abraded skin when applied at a dose of 100 mg/site/day for 5 days.

## REFERENCES

1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition. Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne, PA, January 2000.
2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Seventh Edition. Approved Standard NCCLS Document M2-A7, Vol. 20, No. 1, NCCLS, Wayne, PA, January 2000.
3. National Committee for Clinical Laboratory Standards. Tenth Informational Supplement. Approved NCCLS Document M100-S10, Vol. 20, No. 1, NCCLS, Wayne, PA, January 2000.
4. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. *Clin Infect Dis* 2001; 32:402-12.
5. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections: *Antimicrob Agents Chemother* 2000; 44(12):3408-13.
6. Clemett D and Markham A. Linezolid. *Drugs* 2000; 59(4): 815-27.
7. Walker SE, Shulman KI, Taylor SA, Gardner D. Tyramine content of previously restricted food in monoamine oxidase inhibitor diets. *J Clin Psychopharmacol* 1996; 16(5):583-8.
8. Pfizer Canada Inc., Product Monograph, ZYVOXAM (Linezolid tablet) 600 mg, Control Number: 211843, Date of Revision: February 9, 2018
9. Product Monograph- SANDOZ LINEZOLID (Linezolid Tablets), Sandoz Canada Inc., Date of Preparation: May 10, 2018, Control No.: 215583.

## **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION**

### **Pr JAMP Linezolid Linezolid tablets**

Read this carefully before you start taking JAMP Linezolid and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about JAMP Linezolid.

#### **What is JAMP Linezolid used for?**

JAMP Linezolid is an antibiotic medicine. It is used to treat the following bacterial infections in adults:

- abdomen infections
- skin infections
- infections of system that carries urine out of body (urinary tract)
- lung infections (pneumonia)

Antibacterial drugs like JAMP Linezolid treat only bacterial infections. They do not treat viral infections. Although you may feel better early in treatment, JAMP Linezolid should be used exactly as directed. Misuse or overuse of JAMP Linezolid could lead to the growth of bacteria that will not be killed by JAMP Linezolid (resistance). This means that JAMP Linezolid may not work for you in the future. Do not share your medicine.

#### **How does JAMP Linezolid work?**

JAMP Linezolid belongs to the class of medicines called oxazolidinones antibiotics. It works by stopping the growth of bacteria responsible for your infection.

#### **What are the ingredients in JAMP Linezolid?**

Medicinal ingredient: Linezolid

Non-medicinal ingredients: Colloidal silicon dioxide, corn starch, hydroxypropylcellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, titanium dioxide.

#### **JAMP Linezolid comes in the following dosage forms:**

Tablets: 600 mg

#### **Do not use JAMP Linezolid if you:**

- are allergic to linezolid or any other ingredients of JAMP Linezolid (see What are the ingredients in JAMP Linezolid?).
- have uncontrolled high blood pressure
- have pheochromocytoma [a tumor of small part of the body, located on top of each kidney (adrenal gland)]
- have thyrotoxicosis (an overactive thyroid)
- have carcinoid syndrome (a condition caused by tumours of the hormone system with signs

of diarrhea, skin flushing, rapid heartbeat, wheezing)

- have taken certain medications used for low mood (depression) like isocarboxazid, phenelzine or tranylcypromine or medications used for Parkinson's disease like selegiline or rasagiline in the last 14 days
- are taking any cold or flu medication containing pseudoephedrine or phenylpropanolamine\*
- are taking epinephrine, a medication used for severe allergic reactions
- are taking any other medication that increases blood pressure like norepinephrine, dopamine or dobutamine
- are taking any medication known as selective serotonin re-uptake inhibitors (SSRI's) (e.g., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) or serotonin norepinephrine reuptake inhibitors (SNRIs) (e.g., desvenlafaxine, duloxetine, venlafaxine ). These medications may be used for low mood (depression).
- are taking tricyclic antidepressants, medications for low mood such as amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline
- are taking medications for migraine such as almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
- are taking meperidine, a medication for pain
- are taking buspirone, a medication for anxiety

\* phenylpropanolamine is no longer marketed in Canada

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take JAMP Linezolid. Talk about any health conditions or problems you may have, including if you:**

- have a history of high blood pressure.
- have taken a drug for low mood (depression) within the last 2 weeks (14 days).
- have a history of anemia (low red blood cells), thrombocytopenia [(low cells in the blood that help the blood clot (platelets)], neutropenia (low white blood cells) or any other blood related problems.
- have a history of bleeding problems.
- have a history of seizures or convulsions.
- have diabetes. You will need to watch your blood sugar closely.
- are pregnant or trying to become pregnant.
- are breast-feeding.

**Other warnings you should know about:**

While taking JAMP Linezolid

- Follow your doctor's instructions carefully.
- Do not stop taking your medicine until your doctor tells you to, even if you are feeling better. JAMP Linezolid is not normally used in children and teenagers under 18 years old.
- If you develop severe diarrhea during or over 2 months after treatment with JAMP Linezolid, call your healthcare professional immediately (see What are possible side effects from using JAMP Linezolid? section below).
- Do not use any medicine to treat your diarrhea without first checking with your doctor.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with JAMP Linezolid:**

- All the medications listed under “Do not use JAMP Linezolid if you” section above. Many other medications may also interact with JAMP Linezolid. Tell your healthcare professional about all the medications you are taking, even those that do not appear on this list.
- Tyramine, a chemical naturally present in some pickled, smoked, or fermented foods or drinks like aged cheese and red wines. This interaction may cause a sudden increase in your blood pressure. If you develop a throbbing headache after eating or drinking, tell your healthcare professional. To prevent these problems, get a list of tyramine-rich foods to avoid from your healthcare professional while taking JAMP Linezolid.

**How to take JAMP Linezolid:**

You may take JAMP Linezolid (tablets) with or without food.

**Usual dose (adults, 18 years and older):**

One tablet (600 mg) twice a day (every 12 hours) for 10 to 28 days.

Your healthcare professional will tell you how long you need to take JAMP Linezolid.

**Overdose:**

If you think you, or a person you are caring for, have taken too much JAMP Linezolid, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

**Missed Dose:**

If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule as prescribed by your doctor. **Do not take double doses to make up for missing a dose.**

**What are possible side effects from using JAMP Linezolid?**

These are not all the possible side effects you may feel when taking JAMP Linezolid. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- Headache
- Diarrhea
- Nausea
- Vomiting
- Dizziness
- Change in taste
- Fungal infection
  - white patches in mouth, tongue or throat (oral thrush)
  - for women, vaginal yeast infection with itching and irritation in the vagina, pain or

burning when urinating (peeing), vaginal discharge

- Tongue discoloration
- Fever
- Insomnia
- Constipation
- Rash
- Dry mouth
- Stomach discomfort
- Increased thirst
- High blood sugar (blurred vision, unusual thirst, increased frequency and amount of urination, a fruit-like breath odor, rapid breathing)
- Low blood sugar (dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating)
- Ringing in the ear
- High blood pressure (watch your blood pressure closely)

<b>Serious side effects and what to do about them</b>			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNCOMMON <b>Blood problems</b> (decrease in the level of blood cells): Unusual bleeding or bruising, feeling very tired or weak shortness of breath, fever and chills, sore throat		√	
<b>Vision problems:</b> blurred vision, changes in colour vision, loss of vision		√	
Numbness, tingling, prickling sensations or burning pain		√	
<b>Signs of too much lactic acid in the blood</b> (lactic acidosis): feeling very tired or weak, feeling cold, severe nausea with or without vomiting, stomach pain, fast breathing, fast heartbeat, a heartbeat that does not feel normal, muscle pain or cramps			√
<b>Allergic reactions:</b> rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing; swelling of the mouth, face,			√

<b>Serious side effects and what to do about them</b>			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>Clostridium difficile colitis</b> (bowel inflammation): severe diarrhea (bloody or watery) with or without fever, abdominal pain, or tenderness			√
<b>Serotonin syndrome</b> (occur within several hours of starting a new medicine or increasing the dose of a drug you are already taking): severe headache, agitation, fever, fast heartbeat, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly, severe upset stomach and throwing up, severe loose stools			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### Storage:

Store at room temperature, 15°C to 30°C. Keep out of the reach and sight of children.

### If you want more information about JAMP Linezolid:

- Talk to your healthcare professional
- Find the full Product Monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug->

[product-database.html](#)), the manufacturer's website (www.jamppharma.com), or by calling 1-866-399-9091.

This leaflet was prepared by  
JAMP Pharma Corporation  
1310 rue Nobel  
Boucherville, Quebec  
J4B 5H3, Canada

Last revised: September 13, 2021